Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion

NCT00065429 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT00065429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00065429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2003
Completion date
December 31, 2008
Enrollment
64 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer